Clinical trials - Press Releases

Date	Title	Company
15-Dec-2022	CellProthera expands clinical trial sites for phase IIb myocardial infarction study	CellProthera
15-Dec-2022	THOUSANDS OF PATIENTS WITH TERMINAL LUNG SCARRING GIVEN ACCESS TO DRUGS THAT COULD PROLONG THEIR LIVES	• Action for Pulmonary Fibrosis
15-Dec-2022	Data Shows 50% of New Trials Have Sites in Asia Pacific	Novotech Health Holdings Pte Ltd
15-Dec-2022	ImaginAb Launches Phase II C-IT Neo Trial using CD8+ Cell Imaging to Investigate Neoadjuvant Immunotherapy	ImaginAb
15-Dec-2022	Preventing Strokes and Heart Attacks Doesn't Have to Come with the Risk of Life-threatening Bleeding	Verseon International Corporation
14-Dec-2022	Conference Co-chairs from Merck & AstraZeneca invitation to join 3D Cell Culture	SAE Media Group
13-Dec-2022	Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma	Enterome
13-Dec-2022	Curebase Releases Diagnostic Offering that Delivers First All-Inclusive Package of Software and Services Needed to Fully Execute Diagnostic Studies	Curebase
13-Dec-2022	CluePoints Appoints Andy Cooper as New Chief Executive Officer	CluePoints
13-Dec-2022	1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors	1ST Biotherapeutics, Inc.
12-Dec-2022	Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma	Enterome
09-Dec-2022	Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid▼ showing statistically significant relative risk reduction in major adverse CV events1,2	Daiichi Sankyo UK
09-Dec-2022	Autolus announces FELIX trial of obe-cel meets its primary endpoint	Syncona Ltd
08-Dec-2022	iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289	iOnctura
08-Dec-2022	PHASTAR Joins Oncology Development Programme (ODP2) to Accelerate Development of Novel Cancer Innovations	PHASTAR
08-Dec-2022	Almac Clinical Technologies announces IXRS®3 as market leading in key industry report	Almac
08-Dec-2022	Bloomsbury Genetic Therapies Announces CTA Filing for a Phase I/II Study for its Lead Gene Therapy Program	Bloomsbury Genetic Therapies
08-Dec-2022	The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis	UCB
08-Dec-2022	MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients	MetrioPharm AG
06-Dec-2022	Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials	Novotech Health Holdings Pte Ltd